- Jaimed CEO Sangmin Park Presents Medical AI Generational Change and Trust Assurance Measures
- Next-Generation Medical Trust Strategy Using Atherosclerosis Fundus AI Solution and Explainable AI (XAI) Technology
Jaimed Co., Ltd. (CEO Sangmin Park) successfully delivered a presentation titled "Generational Change and Reliability Assurance in Medical AI: Accuracy, Clinical Utility, and Explainability" at the 2025 ICT Industry Outlook Conference held on November 15.
Hosted by the Ministry of Science and ICT, this conference was organized under the theme "Korea's New Leap in the Digital and AI Era," providing a platform to explore domestic and international ICT outlooks and Korea's response strategies. At the event, CEO Sangmin Park of Jaimed emphasized the need to secure reliability amid the rapidly evolving new generation of medical AI and shared the company's latest AI technology developments and application cases.
In his presentation, CEO Park highlighted the transition process from the first to the third generation of medical AI, explaining that it started with expert systems in the first generation, moved through deep learning-based second generation, and has now entered the third generation represented by foundation models and generative AI. However, he stressed that with the expansion of third-generation AI models, medical AI faces challenges related to opacity and the need to ensure reliability.
CEO Park particularly introduced Jaimed's "explainable artificial intelligence (eXplainable AI·XAI)" technology aimed at addressing the critical issue of reliability in medical AI. Jaimed has adopted technologies such as "Counterfactual AI," which can explain AI's diagnostic process, and "Auditing AI," which monitors AI, focusing on enabling understanding and trust in the rationale behind AI-generated results. Jaimed's counterfactual generation technology clearly demonstrates the AI decision-making process, providing trustworthy information to medical professionals and patients. Through this, the company aims to enhance the reliability of AI models and expand their applicability in real clinical settings.
Jaimed has developed the "Atherosclerosis Fundus AI Solution (FUNDUS-CVDAI)," which predicts cardiovascular risks through non-invasive fundus photography, and recently obtained product approval from the Ministry of Food and Drug Safety. This AI solution captures images of the retina and blood vessels to predict cardiovascular risk levels, offering analysis results conveniently without complicated procedures.
As a tenant company of Seoul Bio Hub, Jaimed continues research to develop cutting-edge technologies in the bio and medical fields. Seoul Bio Hub supports Jaimed with specialized infrastructure and a global network, providing essential research collaboration and investment opportunities throughout Jaimed's medical AI development and commercialization processes. Based on this support, Jaimed is accelerating the development of explainable AI (eXplainable AI·XAI) technology and focusing on securing reliability and accuracy in medical practice.
Jaimed is currently conducting a pilot operation project for the Atherosclerosis Fundus AI Solution (FUNDUS-CVD AI) and achieving results, while actively seeking investment for full-scale product commercialization. In addition to the fundus diagnostic AI solution, the company plans to expand its AI product lineup into opportunity screening areas. Through a diversified AI medical device portfolio, Jaimed aims to meet the demands of the medical market and strengthen its position in both domestic and international healthcare markets.
Through this presentation, Jaimed proposed measures to ensure the reliability of medical AI and its practical applicability, demonstrating that Korea's innovative medical AI technology can play a leading role on the global stage amid the rapidly changing medical AI environment.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
